Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy

scientific article

Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S40120-015-0027-Z
P932PMC publication ID4470972
P698PubMed publication ID26847675
P5875ResearchGate publication ID276640013

P50authorAntonio BertolottoQ57068828
P2093author name stringFabiana Marnetto
Marco Capobianco
Simona Malucchi
Alessia Di Sapio
Arianna Sala
Yana Motuzova
P2860cites workMultiple sclerosis following etanercept treatment for ankylosing spondylitisQ43810403
Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.Q50876825
CNS demyelination during anti–tumor necrosis factor alpha therapyQ59758980
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupQ78130683
Neuromyelitis optica: importance of cerebrospinal fluid examination during relapseQ79255390
Adalimumab-associated multiple sclerosisQ79539057
Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytesQ28219857
Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the LiteratureQ30647378
Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological studyQ34501045
Tumor necrosis factor-alpha antagonists and neuropathyQ37015624
The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.Q37365418
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapyQ37443488
Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitorsQ37911726
Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseasesQ37930148
Demyelination and other neurological adverse events after anti-TNF therapyQ38137583
The scavenger receptor CD36 plays a role in cytokine-induced macrophage fusionQ42155690
P433issue1
P921main subjectcerebrospinal fluidQ54196
P304page(s)53-60
P577publication date2015-03-06
P1433published inNeurology and therapyQ26842826
P1476titlePeculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-α Therapy
P478volume4

Search more.